[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557897":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":37,"locations":45,"responsibleParty":63,"collaborators":65,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":10,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":10,"studyType":109,"phases":10,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Hepatocellular carcinoma group",null,"Patients with histologically or cytological, imaging confirmed untreated hepatocellular carcinoma.",[13],"Diagnostic Test: Proteomics",{"label":15,"type":10,"description":16,"interventionNames":17},"Benign liver lesions group","Untreated patients with confirmed or suspected benign liver lesions by histopathology, or with high suspicion of benign liver lesions by imaging evaluation or other routine clinical diagnosis",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Healthy people group","People without any liver disease",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","Proteomics","Proteomic is performed on all blood samples.",[15,19,9],[29,33,35],{"name":30,"affiliation":31,"role":32},"Weilin Wang","2nd Affiliated Hospital, School of Medicine, Zhejiang University, China","PRINCIPAL_INVESTIGATOR",{"name":34,"affiliation":31,"role":32},"Yuan Ding",{"name":36,"affiliation":31,"role":32},"Zhongquan Sun",[38,42],{"name":30,"role":39,"phone":40,"phoneExt":10,"email":41},"CONTACT","13606642087","wam@zju.edu.cn",{"name":34,"role":39,"phone":43,"phoneExt":10,"email":44},"18858101960","dingyuan@zju.edu.cn",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"2nd Affiliated Hospital, School of Medicine, Zhejiang University","RECRUITING","Hangzhou","Zhejiang","310009","China","CN",{"type":55,"coordinates":56},"Point",[57,58],120.16142,30.29365,{"lat":58,"lon":57},[61],{"name":30,"role":39,"phone":62,"phoneExt":10,"email":41},"+86 13606642087",{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[66,68,70,72,74,76,79,81,83,85,87,89,91,93],{"name":67,"class":6},"First Affiliated Hospital of Harbin Medical University",{"name":69,"class":6},"Zhongnan Hospital",{"name":71,"class":6},"First Affiliated Hospital of Wenzhou Medical University",{"name":73,"class":6},"Jinhua Municipal Central Hospital",{"name":75,"class":6},"Third Affiliated Hospital, Sun Yat-Sen University",{"name":77,"class":78},"Anhui Provincial Hospital","OTHER_GOV",{"name":80,"class":6},"Beijing Tsinghua Changgeng Hospital",{"name":82,"class":6},"Qilu Hospital of Shandong University",{"name":84,"class":6},"West China Hospital",{"name":86,"class":6},"The First Affiliated Hospital of Zhengzhou University",{"name":88,"class":6},"Third Affiliated Hospital of Xinjiang Medical University",{"name":90,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"name":92,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":94,"class":6},"Wuhan TongJi Hospital","100557897","early-stage-detection-of-liver-cancer-by-proteins-in-peripheral-blood-100557897",false,"NCT06544083","Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood","Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood: a Multi-center, Prospective Study","Inclusion Criteria:\n\n1. Voluntarily sign informed consent.\n2. Male or female, age equal to or greater than 18 years and less than 75 years.\n3. Patients with liver cancer who have been diagnosed or suspected for the first time within 42 days prior to blood collection\n4. The subject has not undergone any local or systemic anti-tumor therapy before blood collection, including (but not limited to) tumor surgical treatment for any purpose, local or systemic chemoradiotherapy, targeted therapy (including anti-angiogenic drugs), immunotherapy, cancer vaccine and hormone therapy, etc.\n5. Patients with histologically or cytological, radiographically confirmed hepatocellular carcinoma.\n\nExclusion Criteria:\n\n1. Female subjects who are pregnant or breastfeeding.\n2. Previous organ transplantation or non-autologous bone marrow or stem cell transplantation.\n3. Received drugs with anti-tumor effects for other diseases within 30 days before blood collection, such as drugs used for the treatment of immunorheumatic diseases such as methotrexate, cyclophosphamide, thiazoprine, chlorambucil, etc., drugs for the treatment of breast diseases, such as tamoxifen, etc.\n4. History of previous malignant tumors.\n5. Having other malignant tumors or multiple primary tumors at the same time.",true,"ALL","18 Years","75 Years",{"count":107,"type":108},600,"ESTIMATED","OBSERVATIONAL","By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were identified to accurately establish an early diagnosis model for liver cancer and verify its efficacy.",[112],"Hepatocellular Carcinoma",[112,114],"Diagnosis","2026-05-24",{"date":117,"type":118},"2026-05-27","ACTUAL",{"date":120,"type":118},"2024-02-05",{"date":122,"type":108},"2026-12-31",{"name":5,"class":6},1]